Long-Term Potentiation Is Increased in the CA1 Area of the Hippocampus of APPswe/ind CRND8 Mice

doi:10.1006/nbdi.2002.0557

Neurobiology of Disease

Volume 11, Issue 3, December 2002, Pages 394-409

https://doi.org/10.1006/nbdi.2002.0557 Get rights and content

Abstract

The present study reports changes in synaptic function and plasticity [long-term potentiation (LTP)] in a recently developed mouse model of Alzheimer's disease (CRND8 line) harboring a double amyloid precursor protein mutation (APP_swe/ind). In 9-week-old preplaque transgenic (Tg) mice brain slices, basal synaptic function in the hippocampal CA1 area was unchanged. Only one of three different LTP induction protocols revealed early influence of genotype on synaptic plasticity. By 20 weeks of age, there were numerous plaques in the hippocampus from Tg mice associated with more robust evidence for genotype-related effects in synaptic function. Field potential maximum slope was consistently decreased and LTP was increased, irrespective of the stimulation protocol used. In addition, there was clear evidence of increased synaptic excitability in Tg mice. Furthermore, the maximum amplitude of evoked IPSCs was decreased whereas the maximum amplitude of evoked EPSCs was increased in 20-week-old Tg mice. Collectively, these results suggest a number of APP genotype-related changes in the fine-tuning of the CA1 area circuitry, some of which are likely to contribute to the pathology-dependent effects on LTP observed in CRND8 mice.

References (50)

M.I. Banks et al.
Interactions between distinct GABA(A) circuits in hippocampus
Neuron
(2000)
M.A. Chishti et al.
Early-onset amyloid deposition and cognitive deficits in transgenic mice expressing a double mutant form of amyloid precursor protein 695
J. Biol. Chem.
(2001)
G.R. Dawson et al.
Age-related cognitive deficits, impaired long-term potentiation and reduction in synaptic marker density in mice lacking the beta-amyloid precursor protein
Neuroscience
(1999)
S.M. Fitzjohn et al.
Similar levels of long-term potentiation in amyloid precursor protein-null and wild-type mice in the CA1 region of picrotoxin treated slices
Neurosci. Lett.
(2000)
K. Furukawa et al.
Secreted amyloid precursor protein alpha selectively suppresses N-methyl-d-aspartate currents in hippocampal neurons: Involvement of cyclic GMP
Neuroscience
(1998)
J. Giacchino et al.
In vivo synaptic transmission in young and aged amyloid precursor protein transgenic mice
Brain Res.
(2000)
J. Hardy
Amyloid, the presenilins and Alzheimer's disease
Trends Neurosci.
(1997)
A. Itoh et al.
Impairments of long-term potentiation in hippocampal slices of beta-amyloid-infused rats
Eur. J. Pharmacol.
(1999)
J. Larson et al.
Alterations in synaptic transmission and long-term potentiation in hippocampal slices from young and aged PDAPP mice
Brain Res.
(1999)
R.C. Malenka
Synaptic plasticity in the hippocampus: LTP and LTD
Cell
(1994)

M.P. Mattson et al.

Evidence for excitoprotective and intraneuronal calcium-regulating roles for secreted forms of the beta-amyloid precursor protein

Neuron

(1993)

M. Noda et al.

Glutamate release from microglia via glutamate transporter is enhanced by amyloid-beta peptide

Neuroscience

(1999)

M. Pakaski et al.

Vulnerability of small GABAergic neurons to human beta-amyloid pentapeptide

Brain Res.

(1998)

A. Parent et al.

Synaptic transmission and hippocampal long-term potentiation in transgenic mice expressing FAD-linked presenilin 1

Neurobiol. Dis.

(1999)

Y. Perez et al.

Differential induction of long-lasting potentiation of inhibitory postsynaptic potentials by theta patterned stimulation versus 100-Hz tetanization in hippocampal pyramidal cells in vitro

Neuroscience

(1999)

M. Sawada et al.

Amyloid beta proteins reduce the GABA-induced Cl-current in identified Aplysia neurons

Neurosci. Lett.

(1996)

I. Schneider et al.

Mutant presenilins disturb neuronal calcium homeostasis in the brain of transgenic mice, decreasing the threshold for excitotoxicity and facilitating long-term potentiation

J. Biol. Chem.

(2001)

G.R. Seabrook et al.

Modulation of long-term potentiation in CA1 region of mouse hippocampal brain slices by GABAA receptor benzodiazepine site ligands

Neuropharmacology

(1997)

G.R. Seabrook et al.

Transgenic animals relevant to Alzheimer's disease

Neuropharmacology

(1999)

G.R. Seabrook et al.

Mechanisms contributing to the deficits in hippocampal synaptic plasticity in mice lacking amyloid precursor protein

Neuropharmacology

(1999)

J. Wu et al.

Beta-amyloid-(1–40) increases long-term potentiation in rat hippocampus in vitro

Eur. J. Pharmacol.

(1995)

L. Ye et al.

Suppressive action produced by beta-amyloid peptide fragment 31–35 on long-term potentiation in rat hippocampus is N-methyl-d-aspartate receptor-independent: It's offset by (−)huperzine A

Neurosci. Lett.

(1999)

S.H. Zaman et al.

Enhanced synaptic potentiation in transgenic mice expressing presenilin 1 familial Alzheimer's disease mutation is normalized with a benzodiazepine

Neurobiol. Dis.

(2000)

C. Arias et al.

Beta-amyloid peptide fragment 25–35 potentiates the calcium-dependent release of excitatory amino acids from depolarized hippocampal slices

J. Neurosci. Res.

(1995)

Cited by (78)

Spatial Disorientation Under Dark Conditions Across Development in an Alzheimer's Disease Mouse Model
2023, Neuroscience
Alzheimer’s disease (AD) is associated with hippocampal neuropathology and cognitive impairments, including wandering behavior or becoming lost in a familiar environment. Wandering behavior is severe and manifests early in life for people with specific genetic mutations. Genetic mouse models of AD have been developed to characterize the onset and progression of behavioral deficits that represent human behaviors, such as wandering, to test the efficacy of therapeutics. It is not clear if current assessments of mouse models capture the onset of AD or a snapshot of its progression. Sequential analysis of open field behavior provides a robust, quick test to dissociate navigation cues that contribute to spatial disorientation, a feature of wandering. Despite potential utility in evaluating this feature of AD, little work has been reported using animal models of dementia in this task. Thus, we examined the use of different sources of information to maintain spatial orientation at two prodromal ages in female transgenic CRND8 AD (n = 17) and Control mice (n = 16). These mice exhibit amyloid plaques, a hallmark neuropathological feature of AD, that are associated with cognitive dysfunction at ∼three months of age. Spatial disorientation was observed at two months and more severely at four months under dark conditions, but performance was spared when visual environmental cues were available. This study provides documentation of impaired self-movement cue processing in AD mice, establishing the dark open field as a behavioral tool to characterize spatial disorientation associated with AD. These findings may accelerate future assessments of novel therapeutic interventions for neurological disorders.
The three sisters of fate: Genetics, pathophysiology and outcomes of animal models of neurodegenerative diseases
2022, Neuroscience and Biobehavioral Reviews
Alzheimer’s disease (AD), Parkinson’s disease (PD), and Huntington’s disease (HD) are neurodegenerative disorders characterized by progressive structural and functional loss of specific neuronal populations, protein aggregation, an insidious adult onset, and chronic progression. Modeling AD, PD, and HD in animal models is useful for studying the relationship between neuronal dysfunction and abnormal behaviours. Animal models are also excellent tools to test therapeutic approaches. Numerous genetic and toxin-induced models have been generated to replicate these neurodegenerative disorders. These differ in the genetic manipulation employed or the toxin used and the brain region lesioned, and in the extent to which they mimic the neuropathological and behavioral deficits seen in the corresponding human condition. Each model exhibits unique advantages and drawbacks. Here we present a comprehensive overview of the numerous AD, PD, and HD animal models currently available, with a focus on their utilities and limitations. Differences among models might underlie some of the discrepancies encountered in the literature and should be taken into consideration when designing new studies and testing putative therapies.
Strain differences in hippocampal synaptic dysfunction in the TgCRND8 mouse model of Alzheimer's disease: Implications for improving translational capacity
2019, Molecular and Cellular Neuroscience
Citation Excerpt :
Its protein product, CaMKIIα, has been shown to be required for hippocampal-associated spatial learning (Silva et al., 1992a), memory consolidation (Frankland et al., 2001), and intact hippocampal LTP (Silva et al., 1992b), making it an attractive candidate to potentially explain some of the phenotypic strain differences reported in the literature. Importantly, this is the first examination of basal and synaptic function in the 129 TgCRND8 model, in which several parameters were severely affected by the AD-like mutations, as all prior published studies of synaptic function in this model have been in mice maintained on C3H hybrid backgrounds (Jolas et al., 2002; Kimura et al., 2012; Arrieta-Cruz et al., 2010) or un-specified backgrounds (Tozzi et al., 2015). This may possibly be due in part to C3H being favored in experimental designs due to the increased mortality rate of 129 Tg (25% survival rate by 12 months) relative to C3H Tg mice (50% survival rate by 12 months; (Chishti et al., 2001)) and the resulting difficulties in establishing older experimental groups.
In Alzheimer's disease (AD), characterized by cognitive deterioration, synaptic alterations are frequently reported. The TgCRND8 model, in which mice develop AD-like amyloid β plaque formation, has been used to investigate the effects of amyloidosis on synaptic function. Background strain impacts the behavioral and neuropathological phenotype of mice in this model, but whether this extends to synaptic function is unknown. We investigated the influence of background strain on basal synaptic transmission and long-term potentiation (LTP) in the hippocampus of TgCRND8 mice (13–16 months) on hybrid backgrounds of (129SvEv/Tac) x (C3H/C57/129SvEv/Tac) (aka “129”) or (C57) x (C3H/C57) (aka “C3H”). In littermate controls, basal synaptic transmission was significantly reduced, whereas the amplitude of excitatory postsynaptic potentials was significantly higher after LTP induction in 129 vs. C3H mice. In 129 TgCRND8 mice, deficits in hippocampal LTP were more severe than in C3H TgCRND8 relative to controls. Compared to controls, network excitability was decreased in transgenics from both strains. These data suggest that 129 TgCRND8 mice are the more appropriate model to evaluate the efficacy of potential AD treatments on synaptic function, owing to their significant deficit in LTP. Such studies are critical in order to improve the translational capacity of basic science research.
SUMO1 impact on Alzheimer disease pathology in an amyloid-depositing mouse model
2018, Neurobiology of Disease
Small ubiquitin-related modifiers (SUMOs) conjugated or bound to target proteins can affect protein trafficking, processing and solubility. SUMOylation has been suggested to play a role in the amyloid plaque and neurofibrillary tangle pathology of Alzheimer disease (AD) and related neurodegenerative diseases. The current study examines the impact of SUMO1 on processing of the amyloid precursor protein (APP) leading to the production and deposition of the amyloid-β (Aβ) peptide. An in vivo model of these pathways was developed by the generation of double transgenic mice over-expressing human SUMO1 and a mutant APP. The SUMO1-APP transgenics displayed normal APP processing but, at later ages, exhibited increased insoluble Aβ and plaque density accompanied by increased dendritic spine loss, more pronounced synaptic and cognitive deficits. These findings suggest a potential impairment in Aβ clearance as opposed to increased amyloid production. Examination of microglia indicated a reduction in the SUMO1-APP transgenics which is a possible mechanism for the SUMO1-mediated increase in amyloid load. These findings suggest an indirect activity of SUMO1 possibly in the removal of Aβ plaques rather than a direct impact on amyloid generation.
Involvement of GluN2B subunit containing N-methyl-D-aspartate (NMDA) receptors in mediating the acute and chronic synaptotoxic effects of oligomeric amyloid-beta (Aβ) in murine models of Alzheimer's disease (AD)
2017, Neuropharmacology
To elucidate whether a permanent reduction of the GluN2B subunit affects the pathology of Alzheimer's disease (AD), we cross-bred mice heterozygous for GluN2B receptors in the forebrain (hetGluN2B) with a mouse model for AD carrying a mutated amyloid precursor protein with the Swedish and Arctic mutation (mAPP) resulting in a hetGluN2B/mAPP transgenic. By means of voltage-sensitive dye imaging (VSDI) in the di-synaptic hippocampal pathway and the recording of field excitatory postsynaptic potentials (fEPSPs), hippocampal slices of all genotypes (WT, hetGluN2B, mAPP and hetGluN2B/mAPP, age 9–18 months) were tested for spatiotemporal activity propagation and long-term potentiation (LTP) induction. CA1-LTP induced by high frequency stimulation (HFS; 100 Hz/1s) was not different in all genotypes. Aβ_1-42 (50 nM)-application reduced potentiation of fEPSP in WT and hetGluN2B/mAPP mice, LTP in mAPP and hetGluN2B mice was not affected. For VSDI a fast depolarization signal was evoked in the granule cell layer and propagation was analysed in hippocampal CA3 and CA1 region before and after theta stimulation (100pulses/5 Hz). LTP was not significantly different between all genotypes. In mAPP mice θ-stim produced an epileptiform activity reflected in a pronounced prolongation of the FDS compared to the other genotypes. In slices of hetGluN2B/mAPP and GluN2B mice, however, these parameters were similar to WT mice indicating a reversal effect of the attenuated GluN2B expression.
The induction of a hetGluN2B mutation in the mAPP reversed some pathophysiological changes on hippocampal LTP and provide further evidence for the involvement of the glutamatergic system in AD and emphasize the GluN2B subunit as a potential target for AD treatment.
Inhibiting tumor necrosis factor-α before amyloidosis prevents synaptic deficits in an Alzheimer's disease model
2016, Neurobiology of Aging
Deficits in synaptic structure and function are likely to underlie cognitive impairments in Alzheimer's disease. While synaptic deficits are commonly found in animal models of amyloidosis, it is unclear how amyloid pathology may impair synaptic functions. In some amyloid mouse models of Alzheimer's disease, however, synaptic deficits are preceded by hyperexcitability of glutamate synapses. In the amyloid transgenic mouse model TgCRND8, we therefore investigated whether early enhancement of glutamatergic transmission was responsible for development of later synaptic deficits. Hippocampi from 1-month-old TgCRND8 mice revealed increased basal transmission and plasticity of glutamate synapses that was related to increased levels of tumor necrosis factor α (TNFα). Treating these 1-month-old mice for 4 weeks with the TNFα inhibitor XPro1595 prevented synaptic deficits otherwise apparent at the age of 6 months. In this mouse model at least, reversing the hyperexcitability of glutamate synapses via TNFα blockade before the onset of amyloid plaque formation prevented later synaptic deficits.

View all citing articles on Scopus

¹: To whom correspondence should be addressed. Fax: (908)740-3294. E-mail: [email protected].

²: These two authors contributed equally to this work.

View full text

Regular ArticleLong-Term Potentiation Is Increased in the CA1 Area of the Hippocampus of APPswe/ind CRND8 Mice

Abstract

Neuron

J. Biol. Chem.

Neuroscience

Neurosci. Lett.

Neuroscience

Brain Res.

Trends Neurosci.

Eur. J. Pharmacol.

Brain Res.

Cell

Neuron

Neuroscience

Brain Res.

Neurobiol. Dis.

Neuroscience

Neurosci. Lett.

J. Biol. Chem.

Neuropharmacology

Neuropharmacology

Neuropharmacology

Eur. J. Pharmacol.

Neurosci. Lett.

Neurobiol. Dis.

Beta-amyloid peptide fragment 25–35 potentiates the calcium-dependent release of excitatory amino acids from depolarized hippocampal slices

J. Neurosci. Res.

Regular Article
Long-Term Potentiation Is Increased in the CA1 Area of the Hippocampus of APP_swe/ind CRND8 Mice